Please ensure Javascript is enabled for purposes of website accessibility

Why Exelixis Stock Is Skyrocketing Today

By Keith Speights – Apr 20, 2020 at 10:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about the biotech's positive news from a key late-stage clinical study.

What happened

Shares of Exelixis (EXEL 1.32%) were skyrocketing 25.5% as of 11:12 a.m. EDT on Monday. The big jump came after Exelixis and Bristol Myers Squibb (BMY 1.04%) announced positive top-line results from a late-stage clinical study evaluating a combination of Opdivo and Cabometyx in previously untreated renal cell carcinoma (RCC). 

So what

RCC is the most common type of kidney cancer in adults and causes more than 140,000 deaths each year across the world. The highest rates of the disease are in North America and Europe. This translates to a significant market opportunity for a safe and effective new treatment for RCC. Based on the phase 3 results announced today, the Opdivo-Cabometyx combo appears to check off both boxes. 

Boxing glove hitting a cancer cell

Image source: Getty Images.

Opdivo and Cabometyx met the primary endpoint of progression-free survival in a head-to-head comparison against Pfizer's Sutent. The combo also met secondary endpoints of overall survival at a pre-specified interim analysis and objective response rate, which is the percentage of patients with a reduction in tumor burden at a pre-defined level. The initial data also showed that a 40 mg dose of the Opdivo-Cabometyx combo demonstrated a favorable safety profile as well.

Exelixis has already achieved tremendous market success with Cabometyx in previously treated RCC and in previously treated hepatocellular carcinoma (HCC), the most common form of liver cancer. The company's growth strategy relies heavily on more regulatory approvals of the drug as part of a combination therapy. 

Now what

For now, regulatory approval is a major hurdle that remains to be jumped. Exelixis chief medical officer Gisela Schwab said, "We look forward to our continued collaboration with Bristol Myers Squibb as we work toward regulatory filings in the near future." The companies also plan to present detailed results from the late-stage study at an upcoming medical conference.

Today's news added fuel to the fire of Exelixis' comeback after the biotech stock dropped more than 30% in March from its highs set earlier this year. Although a potential regulatory approval of Opdivo and Cabometyx won't be in the cards until next year, Exelixis could maintain its momentum with data readouts from several other clinical studies on the way in 2020.

Keith Speights owns shares of Bristol Myers Squibb and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Exelixis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$16.10 (1.32%) $0.21
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$70.88 (1.04%) $0.73
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.18 (0.80%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.